Lipitor marketing dispute
Pfizer conducts 55% of all audited details for the cholesterol lowering drug Lipitor, "and that percentage is rising," Pfizer maintains in response to a Warner-Lambert suit to end the co-promotion agreement. AHP would not be able to match the Pfizer sales force in addressing the cardiovascular market, Pfizer declares. In a Dec. 2 letter to shareholders opposing Pfizer's hostile takeover bid, Warner-Lambert maintains that "we satisfied ourselves that the marketing of Lipitor would not suffer" before suing Pfizer to end the deal
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth